Clinical Trial Detail

NCT ID NCT01625234
Title Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Xcovery Holding Company, LLC
Indications

Advanced Solid Tumor

Therapies

Ensartinib

Age Groups: senior adult

Additional content available in CKB BOOST